Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147357 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL1147354 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL12631853 | 0.86 | LMNA (0.51) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL28900632 | 0.84 | LMNA (0.49) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL1147545 | 0.84 | LMNA (0.52) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL1147373 | 0.83 | LMNA (0.56) | LMNASMN1; SMN2NR4A2CYP1A2ALDH1A1 | |
| SCHEMBL1147644 | 0.83 | LMNA (0.56) | LMNASMN1; SMN2NR4A2CYP1A2ALDH1A1 | |
| SCHEMBL3271877 | 0.82 | NR4A2 (0.49) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL1147640 | 0.82 | LMNA (0.53) | LMNASMN1; SMN2CCR1NR4A2SOS2 | |
| SCHEMBL1147345 | 0.81 | LMNA (0.57) | LMNASMN1; SMN2NR4A2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| EP-1910334-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | Exonhit Therapeutics SA (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| CN-1747952-A | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-03-15 | — | — | CN | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | RB1, ALDH1A2, CDK4 | LMNA 2911/4885SMN1; SMN2 1274/4885CCR1 442/4885 |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | APP, BACE1, IAPP | LMNA 1719/4885SMN1; SMN2 1581/4885CCR1 3582/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | LMNA 2911/4885SMN1; SMN2 1274/4885CCR1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.